Stereotactic body radiotherapy as boost for organ-confined prostate cancer

Technology in Cancer Research and Treatment

Volumn 9, Issue 6, 2010, Pages 575-582

  Katz, Alan J ^a   Santoro, Michael ^a   Ashley, Richard ^a   Diblasio, Ferdinand ^a   Witten, Matthew ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Prostate cancer; Quality of life; Stereotactic body radiotherapy; Toxicity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; EXTERNAL BEAM RADIOTHERAPY; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PROSTATE CANCER; RADIATION DOSE; RECTUM DISEASE; RECTUM HEMORRHAGE; STEREOTACTIC BODY RADIATION THERAPY; URINARY FREQUENCY; URINARY URGENCY; UROGENITAL TRACT DISEASE;

EID: 78650343612     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303461000900605     Document Type: Article

References (39)

1. Bagshaw, M. A., Cox, R. S. , Ray, G. R. Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr 47-60 (1988).
2. Perez, A. A., Pilepich, M. V., Zivnuska, F. Tumor control in definitive irradiation of localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 12, 523-531 (1986).
3. Hanks, G. E., Diamond, J. J., Krall, J. M., Martz, K. L., Kramer, S. A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States. Int J Radiat Oncol Biol Phys 13, 499-505 (1987).
4. Zagars, G. K., von Eschenbach, A. C., Johnson, D. E., Oswald, M. J. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer 60, 1489-1499 (1987).
5. Zietman, A. L., Chung, C. S., Coen, J. J., Shipley, W. U. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol 171, 210-214 (2004).
6. Pollack, A., Zagars, G. K., Starkschall, G., Antolak, J. A., Lee, J. J., Huang, E., von Eschenbach, A. C., Kuban, D.A., Rosen, I. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53, 1097-1105 (2002).
7. Kupelian, P. A., Potters, L., Khuntia, D., Ciezki, J. P., Reddy, C. A., Reuther, A. M., Carlson, T. P., Klein, E. A. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58, 25-33 (2004).
8. Zelefsky, M. J., Chan, H., Hunt, M., Yamada, Y., Shippy, A. M., Amols, H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176, 1415-1419 (2006).
9. Stock, R. G., Stone, N. N., Cesaretti, J. A., Rosenstein, B. S. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64, 527-533 (2006).
10. Stone, N. N., Potters, L., Davis, B. J., Ciezki, J. P., Zelefsky, M. J., Roach, M., Shinohara, K., Fearn, P. A., Kattan, M. W., Stock, R. G. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 73, 341-346 (2009).
11. Sylvester, J. E., Grimm, P. D., Blasko, J. C., Millar, J., Orio, P. F. III., Skoglund, S., Galbreath, R. W., Merrick, G. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 67, 57-64 (2007).
12. Demanes, D. J., Rodriguez, R. R., Schour, L., Brandt, D., Altieri, G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 61, 1306-1316 (2005).
13. Galalae, R. M., Martinez, A., Mate, T., Mitchell, C., Edmundson, G., Nuernberg, N., Eulau, S., Gustafson, G., Gribble, M., Kovacs, G. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58, 1048-1055 (2004).
14. Hiratsuka, J., Jo, Y., Yoshida, K., Nagase, N., Fujisawa, M., Imajo, Y. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys 59, 684-690 (2004).
15. Martinez, A. A., Gustafson, G., Gonzalez, J., Armour, E., Mitchell, C, Edmundson, G., Spencer, W, Stromberg, J., Huang, R., Vicini, F. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53, 316-327 (2002).
16. Phan, T. P., Syed, A. M., Puthawala, A., Sharma, A., Khan, F. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol 177, 123-127; discussion 127 (2007).
17. Romanelli, P., Schaal, D. W., Adler, J. R. Image-guided radiosurgical ablation of intra- and extra-cranial lesions. Technol Cancer Res Treat 5, 421-428 (2006).
18. Wei, J. T., Dunn, R. L., Litwin, M. S., Sandler, H. M., Sanda, M. G. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56, 899-905 (2000).
19. National Institutes of Health: Common toxicity criteria. In., version 2.0 edn: National Institutes of Health 1998.
20. Roach, M., III., Hanks, G., Thames, H., Jr., Schellhammer, P., Shipley, W. U., Sokol, G. H., Sandler, H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65, 965-974 (2006).
21. Zelefsky, M. J., Shi, W., Yamada, Y., Kollmeier, M. A., Cox, B., Park, J., Seshan, V. E. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int J Radiat Oncol Biol Phys 75, 1350-1356 (2009).
22. Pellizzon, A. C., Salvajoli, J., Novaes, P., Maia, M., Fogaroli, R., Gides, D., Horriot, R. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition. Int J Med Sci 5, 113-120 (2008).
23. Izard, M. A., Haddad, R. L., Fogarty, G. B., Rinks, A., Dobbins, T., Katelaris, P. Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer. Int J Radiat Oncol Biol Phys 66, 38-47 (2006).
24. Nickers, P., Coppens, L., de Leval, J., Jansen, N., Deneufbourg, J. M. 192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: a phase II trial. Radiother Oncol 79, 329-334 (2006).
25. Ares, C., Popowski, Y., Pampallona, S., Nouet, P., Dipasquale, G., Bieri, S., Ozsoy, O., Rouzaud, M., Khan, H., Miralbell, R. Hypofractionated Boost with High-Dose-Rate Brachytherapy and Open Magnetic Resonance Imaging-Guided Implants for Locally Aggressive Prostate Cancer: A Sequential Dose-Escalation Pilot Study. Int J Radiat Oncol Biol Phys 75, 656-663 (2009).
26. Kalkner, K. M., Wahlgren, T., Ryberg, M., Cohn-Cedermark, G., Castellanos, E., Zimmerman, R., Nilsson, J., Lundell, M., Fowler, J., Levitt, S., Hellstrom, M., Nilsson, S. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up. Acta Oncol 46, 909-917 (2007).
27. Soumarova, R., Homola, L., Stursa, M., Perkova, H. Acute toxicity of conformal high dose interstitial brachytherapy boost in prostate cancer. Neoplasma 53, 410-417 (2006).
28. Ishiyama, H., Kitano, M., Satoh, T., Kotani, S., Uemae, M., Matsumoto, K., Okusa, H., Tabata, K. I., Baba, S., Hayakawa, K. Genitourinary Toxicity After High-Dose-Rate (HDR) Brachytherapy Combined with Hypofractionated External Beam Radiotherapy for Localized Prostate Cancer: An Analysis to Determine the Correlation Between Dose-Volume Histogram Parameters in HDR Brachytherapy and Severity of Toxicity. Int J Radiat Oncol Biol Phys 75, 23-28 (2009).
29. Zietman, A. L., DeSilvio, M. L., Slater, J. D., Rossi, C. J., Jr., Miller, D. W., Adams, J. A., Shipley, W. U. Comparison of conventional- dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. Jama 294, 1233-1239 (2005).
30. Simone, N. L., Menard, C., Soule, B. P., Albert, P. S., Guion, P., Smith, S., Godette, D., Crouse, N. S., Sciuto, L. C., Cooley-Zgela, T., Camphausen, K., Coleman, C. N., Singh, A. K. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score. Int J Radiat Oncol Biol Phys 70, 90-95 (2008).
31. Duchesne, G. M., Williams, S. G., Das, R., Tai, K. H. Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I/II study results. Radiother Oncol 84, 128-134 (2007).
32. Katz, A., Santoro, M. CyberKnife radiosurgery for early carcinoma of the prostate: A three year experience. Int J Radiat Oncol Biol Phys 75, S312-S313 (2009).
33. Sanda, M. G., Dunn, R. L., Michalski, J., Sandler, H. M., Northouse, L., Hembroff, L., Lin, X., Greenfield, T. K., Litwin, M. S., Saigal, C. S., Mahadevan, A., Klein, E., Kibel, A., Pisters, L. L., Kuban, D., Kaplan, I., Wood, D., Ciezki, J., Shah, N., Wei, J. T. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358, 1250-1261 (2008).
34. Fujioka, H., Ishimura, T., Sakai, Y., Fujii, T., Jo, Y., Takenaka, A., Fujisawa, M. Erectile function after brachytherapy with external beam radiation for prostate cancer. Arch Androl 50, 295-301 (2004).
35. Vicini, F. A., Kestin, L. L., Martinez, A. A. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation. Tech Urol 6, 135-145 (2000).
36. Chen, Y. C., Chuang, C. K., Hsieh, M. L., Chen, W. C., Fan, K. H., Yeh, C. Y., Lee, C. C., Hong, J. H. High-dose-rate brachytherapy plus external beam radiotherapy for T1 to T3 prostate cancer: an experience in Taiwan. Urology 70, 101-105 (2007).
37. Sato, M., Mori, T., Shirai, S., Kishi, K., Inagaki, T., Hara, I. High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer. Int J Radiat Oncol Biol Phys 72, 1002-1009 (2008).
38. Fuller, D. B., Naitoh, J., Lee, C., Hardy, S., Jin, H. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 70, 1588-1597 (2008).
39. Xie, Y., Djajaputra, D., King, C. R., Hossain, S., Ma, L., Xing, L. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 72, 236-246 (2008).